Chiral N,N-disubstituted trifluoro-3-amino-2-propanols are potent inhibitors of cholesteryl ester transfer protein

Journal of Medicinal Chemistry

Volumn 45, Issue 18, 2002, Pages 3891-3904

  Durley, Richard C ^a   Grapperhaus, Margaret L ^a   Hickory, Brian S ^a   Massa, Mark A ^a   Wang, Jane L ^a   Spangler, Dale P ^a   Mischke, Deborah A ^a   Parnas, Barry L ^a   Fobian, Yvette M ^a   Rath, Nigam P ^b   Honda, Dorothy D ^a   Zeng, Ming ^a   Connolly, Daniel T ^a   Heuvelman, Deborah M ^a   Witherbee, Bryan J ^a   Melton, Michele A ^a   Glenn, Kevin C ^a   Krul, Elaine S ^a   Smith, Mark E ^a   Sikorski, James A ^a,c  

^a PFIZER INC   (United States)

^b UNIVERSITY OF MISSOURI ST LOUIS   (United States)

^c AtheroGenics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 [(3 FLUOROPHENYL)[[3 (TRIFLUOROMETHYL)PHENYL]METHYL]AMINO] 1,1,1 TRIFLUORO 2 PROPANOL; 3 [(3 PHENOXYPHENYL)[[3 (1,1,2,2 TETRAFLUOROETHOXY)PHENYL]METHYL]AMINO] 1,1,1 TRIFLUORO 2 PROPANOL; 3 [(3 PHENOXYPHENYL)[[3 (ISOPROPOXY)PHENYL]METHYL]AMINO] 1,1,1 TRIFLUORO 2 PROPANOL; 3 [(3 PHENOXYPHENYL)[[3 (TRIFLUOROMETHYLTHIO)PHENYL]METHYL]AMINO] 1,1,1 TRIFLUORO 2 PROPANOL; 3 [[(3 CYCLOPENTYLPHENYL)METHYL](3 PHENOXYPHENYL)AMINO] 1,1,1 TRIFLUOROPROPAN 2 OL; 3 [[(3 PHENOXYPHENYL)(3,3,3 TRIFLUORO 2 HYDROXYPROPYL)AMINO]METHYL] ALPHA,ALPHA BIS(TRIFLUOROMETHYL)BENZENEMETHANOL; ALCOHOL DERIVATIVE; CHOLESTEROL ESTER TRANSFER PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; UNCLASSIFIED DRUG;

ACYLATION; ALKYLATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHEMICAL MODIFICATION; CHIRALITY; CHOLESTEROL TRANSPORT; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG POTENCY; DRUG STRUCTURE; ENANTIOMER; ENZYME INHIBITION; HUMAN; HYPERCHOLESTEROLEMIA; IC 50; MOUSE; NONHUMAN; OXIDATION; SERUM; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

ANILINE COMPOUNDS; ANIMALS; CARRIER PROTEINS; CHOLESTEROL ESTER TRANSFER PROTEINS; COMBINATORIAL CHEMISTRY TECHNIQUES; CRICETINAE; CRYSTALLOGRAPHY, X-RAY; GLYCOPROTEINS; HUMANS; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; LIPOPROTEINS, VLDL; MALE; MESOCRICETUS; MICE; MICE, INBRED C57BL; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PHENYL ETHERS; PROPANOLAMINES; PROTEIN BINDING; SERUM ALBUMIN; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0037194651     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm020038h     Document Type: Article

References (37)

1. Incidence of coronary heart disease and lipoprotein cholesterol levels. The framingham study
2. The antiatherogenic role of high-density lipoprotein cholesterol
3. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the helsinki heart study. Implications for treatment
4. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol
5. Range of serum cholesterol values in the population developing coronary artery disease
6. Plasma lipid transfer proteins, high-density lipoproteins, and reverse cholesterol transport
7. The discovery of new cholesteryl ester transfer protein inhibitors
8. Cholesteryl ester transfer protein as a potential therapeutic target to improve the HDL to LDL cholesterol ratio
9. Relationship of the cholesteryl ester transfer protein (CETP) to athero-sclerosis
10. Boosting "good" cholesterol
11. Severe atherosclerosis in transgenic mice expressing simian cholesterol transfer protein
12. Bis(2-(acylamino)phenyl) disulfides, 2(acylamino)benzenethiols, and S-(2-(acylamino)phenyl)alkanethioates as novel inhibitors of cholesteryl ester transfer protein
13. A cholesteryl ester transfer protein attenuates atherosclerosis in rabbits
14. Effect of antisense oligonucleotides against cholesteryl ester transfer protein on the development of atherosclerosis in cholesterol-fed rabbits
15. Pros and cons of inhibiting cholesteryl ester transfer protein
16. Serum lipoprotein lipid concentration and composition in homozygous and heterozygous patients with cholesteryl ester transfer protein deficiency
17. Polymorphism with variations in lipoprotein subclasses and coronary heart disease risk. The Framingham Study
18. Genetic cholesteryl ester transfer protein deficiency is extremely frequent in omagari area of Japan; marked hyperalphalipoproteinemia caused by cholesteryl ester transfer protein gene mutation is not a longevity syndrome
19. Relationship of HDL and coronary heart desease to a common amino acid polymorphism in the cholesteryl ester transfer protein in men with and without hyperalphalipoproteinemia
20. Elevated HDL cholesterol is a risk factor for ischemic heart disease in white women when caused by a common mutation in the cholesteryl ester transfer protein gene
21. 1999 George Lyman Duff memorial lecture: Lipid transfer proteins, HDL metabolism, and atherogenesis
22. Stereo-selective mukaiyama-michael/michael/aldol domino cyclization as the key step in the synthesis of pentasubstituted arenes: An efficient access to highly active inhibitors of cholesteryl ester transfer protein (CETP)
23. Discovery of chiral N,N-disubstituted trifluoro-3-amino-2-propanols as potent inhibitors of cholesteryl ester transfer protein
24. Stereospecific inhibition of CETP activity by chiral N,N-disubstituted tri-fluoro-3-amino-2-propanols
25. Chiral synthesis via organoboranes. 40. Selective reductions. 55. A simple one-pot synthesis of the enantiomers of trifluoro-methyloxirane. A general synthesis in high optical purities of α-Trifluoro-methyl secondary alcohols via the ring-cleavage reactions of the epoxide
26. Physical and kinetic character of recombinant human cholesteryl ester transfer protein
27. Novel heteroaryl replacements of aromatic 3-tetrafluoroethoxy substituents in trifluoro-3-(tertiaryamino)-2-propanols as potent inhibitors of cholesteryl ester transfer protein
28. 2-Substituted (2SR)-2-amino-2-((1SR,2SR)-2-carboxycycloprop-1-yl)glycines as potent and selective antagonists of group ii metabotropic glutamate receptors. 2. Effects of aromatic substitution; pharmacological characterization, and bioavailability
29. Structural and functional properties of two mutants of lecithin-cholesterol acyltransferase (T123I and N228K)
30. Quantification of cholesteryl ester transfer protein: Activity and immunochemical assay